Tocilizumab (Actemra)
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-09-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1316909 |
| _version_ | 1827810020181409792 |
|---|---|
| author | Martin Sheppard Faidra Laskou Philip P. Stapleton Shahryar Hadavi Bhaskar Dasgupta |
| author_facet | Martin Sheppard Faidra Laskou Philip P. Stapleton Shahryar Hadavi Bhaskar Dasgupta |
| author_sort | Martin Sheppard |
| collection | DOAJ |
| description | Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview of TCZ including looking into the past at the discovery of interleukin-6 (IL-6) as a pro-inflammatory cytokine. It also looks at how tocilizumab was developed, manufactured and tested to ensure both safety and efficacy in a human population. The article then explores the advantages and disadvantages of using TCZ when compared to other biologics approved in RA, sJIA and pJIA and finally looks ahead to the future and the emerging role of IL-6 and its blockade by TCZ as a treatment for giant cell arteritis (GCA), polymyalgia rheumatica (PMR) and large vessel vasculitis (LVV). |
| first_indexed | 2024-03-11T22:46:50Z |
| format | Article |
| id | doaj.art-5f67450e464645afaf4e5cb29e0cd19c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:46:50Z |
| publishDate | 2017-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-5f67450e464645afaf4e5cb29e0cd19c2023-09-22T08:17:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-09-011391972198810.1080/21645515.2017.13169091316909Tocilizumab (Actemra)Martin Sheppard0Faidra Laskou1Philip P. Stapleton2Shahryar Hadavi3Bhaskar Dasgupta4Southend University Hospital NHS Foundation TrustSouthend University Hospital NHS Foundation TrustSouthend University Hospital NHS Foundation TrustSouthend University Hospital NHS Foundation TrustSouthend University Hospital NHS Foundation TrustTocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview of TCZ including looking into the past at the discovery of interleukin-6 (IL-6) as a pro-inflammatory cytokine. It also looks at how tocilizumab was developed, manufactured and tested to ensure both safety and efficacy in a human population. The article then explores the advantages and disadvantages of using TCZ when compared to other biologics approved in RA, sJIA and pJIA and finally looks ahead to the future and the emerging role of IL-6 and its blockade by TCZ as a treatment for giant cell arteritis (GCA), polymyalgia rheumatica (PMR) and large vessel vasculitis (LVV).http://dx.doi.org/10.1080/21645515.2017.1316909giant cell arteritisinterleukin-6monoclonal antibodyrheumatoid arthritistocilizumabvasculitis |
| spellingShingle | Martin Sheppard Faidra Laskou Philip P. Stapleton Shahryar Hadavi Bhaskar Dasgupta Tocilizumab (Actemra) Human Vaccines & Immunotherapeutics giant cell arteritis interleukin-6 monoclonal antibody rheumatoid arthritis tocilizumab vasculitis |
| title | Tocilizumab (Actemra) |
| title_full | Tocilizumab (Actemra) |
| title_fullStr | Tocilizumab (Actemra) |
| title_full_unstemmed | Tocilizumab (Actemra) |
| title_short | Tocilizumab (Actemra) |
| title_sort | tocilizumab actemra |
| topic | giant cell arteritis interleukin-6 monoclonal antibody rheumatoid arthritis tocilizumab vasculitis |
| url | http://dx.doi.org/10.1080/21645515.2017.1316909 |
| work_keys_str_mv | AT martinsheppard tocilizumabactemra AT faidralaskou tocilizumabactemra AT philippstapleton tocilizumabactemra AT shahryarhadavi tocilizumabactemra AT bhaskardasgupta tocilizumabactemra |